<scp>COVID</scp>
            ‐19 and autoimmune phenomena: Vitiligo after Astrazeneca vaccine

Riquelme, Irene López; Ballesteros, María; Ordóñez, Ana Serrano; Diaz, Daniel Jesús Godoy

doi:10.1111/dth.15502

Cited by 9 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the patient had received the second dose of the AstraZeneca vaccine just a few weeks before the depigmented spots appeared. After reviewing the literature (Table 1 ), we found that some cases of vitiligo related to SARS‐CoV‐2 vaccination had been reported, 6 , 7 , 8 , 9 , 10 , 11 , 12 while no cases of eruptive halo nevi after COVID‐19 vaccination had been described so far. Vitiligo and halo nevi are closely connected to each other and share an immune‐mediated etiopathogenesis.…”

mentioning

confidence: 99%

Eruptive halo nevi: A new COVID‐19 vaccine‐related cutaneous adverse event or a paraneoplastic phenomenon?

Giorgi

Colombo

Gemignani

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Eruptive halo nevi: A new COVID‐19 vaccine‐related cutaneous adverse event or a paraneoplastic phenomenon?

Giorgi

Colombo

Gemignani

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…The systematic review included and analyzed 14 studies. [3][4][5][6][7][8][9][10][11][12][13][14][15][16] We observed hetero- COVID-19 vaccines, regardless of their design, rely on presenting the SARS-CoV-2 spike glycoprotein (SP) antigen to induce immunological memory and neutralizing antibodies. 21 Studies have revealed similarities between fragments of the SARS-CoV-2 SP and mammalian proteins, especially human (Homo sapiens) proteomes.…”

Section: Discussionmentioning

confidence: 99%

“…In our case series, we analyzed a total of 26 patients with vaccine‐associated vitiligo following COVID‐19 vaccination. The systematic review included and analyzed 14 studies 3–16 . We observed heterogeneity in both patient characteristics and the vaccines implicated in postvaccine vitiligo occurrence.…”

Section: Discussionmentioning

confidence: 99%

COVID‐19 vaccine–associated vitiligo: A cross‐sectional study in a tertiary referral center and systematic review

Tsai

2023

The Journal of Dermatology

View full text Add to dashboard Cite

Vitiligo is an autoimmune skin disorder that occurs due to immunemediated loss of functional melanocytes, leading to patchy skin depigmentation. The triggering of an autoimmune phenomena in patients infected with coronavirus disease 2019 (COVID-19) and those receiving COVID-19 vaccinations has been increasingly reported, and these adverse events have also been seen in vitiligo. Cases of new-onset and exacerbation of vitiligo following COVID-19 vaccination have been reported in individuals of all ages, ethnicities, and with different vaccine types. While current guidelines and consensus recommend COVID-19 vaccination for most patients, including those with autoimmune diseases, 1,2 practitioners must assess the risk and potential for disease onset or flare-up. According to the Taiwan Centers for Disease Control, around 21.7 million people in our population have received at least one primary COVID-19 vaccine, with 94% of them having been vaccinated, while 88% have received at least two doses and 74% have received at least three doses. In light of the emergence of new Delta and Omicron variants, booster vaccination programs are now underway to enhance the humoral response. Some eligible groups can now receive the fourth vaccination booster and a fifth booster dose of Moderna's next-generation bivalent vaccine.Our study aims to report the incidence of vitiligo following primary and booster COVID-19 vaccines. We retrospectively reviewed electronic medical records of new-onset and exacerbations of vitiligo following COVID-19 vaccinations at our vitiligo clinic, which is located at a tertiary referral center. In addition, we conducted a systematic review to analyze the current evidence regarding COVID-19 vaccine-associated vitiligo. | MATERIAL S AND ME THODSWe conducted a retrospective study at our vitiligo clinic, which is located at a Taiwanese tertiary medical center (Chang Gung Memorial Hospital, Linkou, and Taipei branches). The study included patients with new-onset vitiligo or exacerbations of preexisting vitiligo that were diagnosed within a month of receiving COVID-19 vaccination between January 1, 2021, and September 30, 2022. We clinically diagnosed vitiligo based on the presence of acquired amelanotic macules and patches with well-defined margins and typical distribution. Wood's lamp examination was used to identify vitiligo lesions

show abstract

“… BNT162b2:31 mRNA-1273: 5 AZD1222: 19 Ad26.COV2: 0 Chilblains-like/pernio 12 Russo et al 188 (3), Paparella et al 189 (1), Davido et al 190 (1), Lopez et al 191 (1), Pileri et al 192 (1), Piccolo et al 193 (1), Pérez-López et al 194 (1), Cameli et al 195 (1), Kha et al 196 (1), Lesort et al 197 (1). BNT162b2:9 mRNA-1273: 2 AZD1222: 1 Ad26.COV2: 0 Vitiligo 11 Kaminetsky et al 198 (1), Militello et al 199 (1), Singh et al 200 (1), Nicolaidou et al 201 (1), Flores-Terry et al 202 (1), Bukhari et al 203 (1), Uğurer et al 204 (1), Ciccarese et al 205 (1), López Riquelme et al 206 (1), Okan et al 207 (1), Caroppo et al 208 (1). BNT162b2: 7 mRNA-1273: 3 AZD1222: 1 Ad26.COV2: 0 Abbreviations : BNT162b2, Pfizer mRNABNT162b2; mRNA-1273, Moderna mRNA-1273; AZD1222, AstraZeneca-Oxford AZD1222; Ad26.COV2, Johnson & Johnson Ad26.COV2.S.…”

Section: Methodsmentioning

confidence: 99%

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

show abstract

COVID ‐19 and autoimmune phenomena: Vitiligo after Astrazeneca vaccine

Cited by 9 publications

References 14 publications

Eruptive halo nevi: A new COVID‐19 vaccine‐related cutaneous adverse event or a paraneoplastic phenomenon?

Eruptive halo nevi: A new COVID‐19 vaccine‐related cutaneous adverse event or a paraneoplastic phenomenon?

COVID‐19 vaccine–associated vitiligo: A cross‐sectional study in a tertiary referral center and systematic review

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Contact Info

Product

Resources

About